Table 3.

Clinical studies of GLP1RAs for the treatment of DM or DM-related diseases

Medicine	Generic Name	First Author	Year	Disease	Model	Findings	Ref.
GLP1RAs	Dulaglutide	Gerstein, H.C.	2020	T2DM	Human	Long-term dulaglutide use might reduce clinically relevant ischemic stroke in people with T2DM	[127]
		Tuttolomondo, A.	2021	T2DM	Human	Positive effects on arterial stiffness and endothelial function indicators in patients with T2DM receiving conventional therapy with daily subcutaneous injections of 1.5 mg dulaglutide	[128]
	Liraglutide	Marso, S.P.	2016	T2DM	Human	The composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke was significantly lower in T2DM patients at high cardiovascular risk	[129]
	Semaglutide	Husain, M.	2019	T2DM	Human	The cardiovascular risk profile of patients with T2DM taking oral semaglutide was not worse than those taking placebo	[130]
		Strain, W.D.	2022	T2DM	Human	Semaglutide treatment reduced stroke risk in patients with T2DM and higher cardiovascular risk compared with placebo treatment	[131]
	Efpeglenatide	Gerstein, H.C.	2021	T2DM	Human	Patients with T2DM who received weekly subcutaneous doses of 4 or 6 mg of efpeglenatide had a lower risk of cardiovascular events than those on placebo	[132]
	Albiglutide	Hernandez, A.F.	2018	T2DM	Human	In patients with T2DM and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events	[133]